Suppr超能文献

神经心源性晕厥:最新药物治疗方法

Neurocardiogenic syncope: latest pharmacological therapies.

作者信息

Chen Lin Y, Shen Win-Kuang

机构信息

Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, Minnesota, MN 55905, USA.

出版信息

Expert Opin Pharmacother. 2006 Jun;7(9):1151-62. doi: 10.1517/14656566.7.9.1151.

Abstract

Neurocardiogenic syncope is a neurally mediated disorder and is a common cause of syncope. The goal of treatment is to prevent recurrences with the aim of improving quality of life and reducing morbidity. Reassurance, in some cases, may suffice. In others, augmenting central blood volume by increasing fluid and/or salt intake is effective. The role of non-pharmacological physical manoeuvres is increasingly recognised, given the increasing clinical trial data supporting their efficacy. This review summarises the clinical evidence for a variety of pharmacological agents. Of these, midodrine appears to have yielded the most consistent favourable outcome. Its use, however, should be reserved for patients with recurrent and refractory syncope.

摘要

神经心源性晕厥是一种神经介导的疾病,是晕厥的常见原因。治疗的目标是预防复发,以提高生活质量并降低发病率。在某些情况下,给予安慰可能就足够了。在其他情况下,通过增加液体和/或盐分摄入来增加中心血容量是有效的。鉴于越来越多的临床试验数据支持其疗效,非药物物理操作的作用越来越受到认可。本综述总结了各种药物的临床证据。其中,米多君似乎产生了最一致的良好结果。然而,其使用应仅限于复发性和难治性晕厥患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验